Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

dnaJP1

Phase 2Small molecule

PProf Salvatore Albani

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Intelligence

NCT07013110

Clinical

Trials by Indication[1]

Intelligence1 trial

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Recruiting·PProf Salvatore Albani·Phase 2·NCT07013110·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dnaJP1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dnaJP1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dnaJP1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prof Salvatore Albani company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PProf Salvatore Albani

Related News